share_log

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

中進醫療 | 6-K:外國發行人報告
美股sec公告 ·  03/30 04:15
牛牛AI助理已提取核心訊息
Jin Medical International Ltd. has received a favorable decision from the Nasdaq Hearings Panel, granting the company's request for continued listing on The Nasdaq Stock Market. This decision comes after the company was previously notified of non-compliance with Nasdaq's Listing Rule 5550(a)(3) due to having fewer than the required 300 public holders. Despite regaining compliance with this rule, Jin Medical International still faced a deficiency for not filing its annual report on Form 20-F for the fiscal year ended September 30, 2023. The Panel has allowed the company to remain listed, with the condition that it files the overdue annual report by May 20, 2024. The company has confirmed that it is working to prepare and file the report within the granted extension period.
Jin Medical International Ltd. has received a favorable decision from the Nasdaq Hearings Panel, granting the company's request for continued listing on The Nasdaq Stock Market. This decision comes after the company was previously notified of non-compliance with Nasdaq's Listing Rule 5550(a)(3) due to having fewer than the required 300 public holders. Despite regaining compliance with this rule, Jin Medical International still faced a deficiency for not filing its annual report on Form 20-F for the fiscal year ended September 30, 2023. The Panel has allowed the company to remain listed, with the condition that it files the overdue annual report by May 20, 2024. The company has confirmed that it is working to prepare and file the report within the granted extension period.
Jin Medical International Ltd.已收到納斯達克聽證小組的贊成決定,批准了該公司繼續在納斯達克股票市場上市的請求。該決定是在該公司此前被告知由於公衆持有人少於所需的300名而未遵守納斯達克上市規則5550(a)(3)之後做出的。儘管恢復了對該規定的遵守,但金醫療國際仍因未提交截至2023年9月30日的財政年度的20-F表年度報告而面臨缺陷。該小組允許該公司繼續上市,條件是該公司必須在2024年5月20日之前提交逾期的年度報告。該公司已確認正在努力在規定的延期內準備和提交報告。
Jin Medical International Ltd.已收到納斯達克聽證小組的贊成決定,批准了該公司繼續在納斯達克股票市場上市的請求。該決定是在該公司此前被告知由於公衆持有人少於所需的300名而未遵守納斯達克上市規則5550(a)(3)之後做出的。儘管恢復了對該規定的遵守,但金醫療國際仍因未提交截至2023年9月30日的財政年度的20-F表年度報告而面臨缺陷。該小組允許該公司繼續上市,條件是該公司必須在2024年5月20日之前提交逾期的年度報告。該公司已確認正在努力在規定的延期內準備和提交報告。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。